Tim Grinstead is Chief Operating Officer at Visus Therapeutics. He has over 25 years of experience managing pharmaceutical operations in a diverse range of organizations that developed and manufactured product categories including biologics, solid oral dose, semi-solids, sustained release and modified release, sterile injectables, long acting injectables and liquid formulations. Prior to joining Visus as COO, he was the Vice President and General Manager for Alkermes, Inc leading their Operations for the manufacture of VIVITROL®, ARISTDA® and RISPERDAL CONSTA® as well as several late-stage clinical products. Prior to Alkermes, Tim worked as the Vice President of Manufacturing for Ophthotech (Iveric Bio), leading their biotech manufacturing that focused on their late-stage clinical pipeline of injectable products for diseases of the eye. Tim also worked at Eurand, Inc (formerly a Division of Wyeth and TPG) where he held various roles in Quality, Manufacturing, Engineering, Supply Chain and General Management for multiple sites in North America launching a series of successful sustained release products in both the branded and generic markets.
Tim holds a MA in Analytical Chemistry and a BA in Synthetic Organic Chemistry from Wright State University as well as financial training from the University of Chicago Booth School of Business.